Timothy P Cripe

List of Publications by Year
in descending order

73 papers	2,274 citations	172457 29 h-index	233421 45 g-index
74 all docs	74 docs citations	74 times ranked	3667 citing authors

#	Article	IF	Citations
1	Immunotherapies for Pediatric Solid Tumors: A Targeted Update. Paediatric Drugs, 2022, 24, 1-12.	3.1	5
2	Clinical outcomes and efficacy of stereotactic body radiation therapy in children, adolescents, and young adults with metastatic solid tumors. British Journal of Radiology, 2022, 95, 20211088.	2.2	1
3	Cardiorespiratory management of Duchenne muscular dystrophy: emerging therapies, neuromuscular genetics, and new clinical challenges. Lancet Respiratory Medicine,the, 2022, 10, 403-420.	10.7	19
4	Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics. Science Advances, 2022, 8, .	10.3	7
5	The effect of emerging molecular and genetic therapies on cardiopulmonary disease in Duchenne muscular dystrophy. Pediatric Pulmonology, 2021, 56, 729-737.	2.0	2
6	Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma. IScience, 2021, 24, 102759.	4.1	1
7	Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy. , 2021, 9, e002939.		1
8	GD2â€directed CARâ€T cells in combination with HGFâ€targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma. International Journal of Cancer, 2020, 146, 3184-3195.	5.1	37
9	Gene Editing Thumbs a Ride with Oncolytic Virotherapy. Molecular Therapy, 2020, 28, 2103-2104.	8.2	3
10	Oncolytic Viruses and Their Potential as a Therapeutic Opportunity in Osteosarcoma. Advances in Experimental Medicine and Biology, 2020, 1258, 77-89.	1.6	3
11	Oncolytic virotherapy: a potential therapeutic approach for cholesteatoma. Current Opinion in Otolaryngology and Head and Neck Surgery, 2020, 28, 281-285.	1.8	0
12	A Novel Pathogenic Variant in CARMIL2 (RLTPR) Causing CARMIL2 Deficiency and EBV-Associated Smooth Muscle Tumors. Frontiers in Immunology, 2020, 11, 884.	4.8	26
13	Pediatric cancer research: Surviving COVIDâ€19. Pediatric Blood and Cancer, 2020, 67, e28435.	1.5	28
14	Drug Targeting the Actin Cytoskeleton Potentiates the Cytotoxicity of Low Dose Vincristine by Abrogating Actin-Mediated Repair of Spindle Defects. Molecular Cancer Research, 2020, 18, 1074-1087.	3.4	15
15	A pediatric and young adult phase I dose escalation study of BXQ-350 for solid and central nervous system tumors.. Journal of Clinical Oncology, 2020, 38, 2541-2541.	1.6	2
16	Relationship of infusion duration to safety, efficacy, and pharmacodynamics (PD): Second part of a phase I-II study using VSV-IFNÎ²-NIS (VV1) oncolytic virus in patients with refractory solid tumors.. Journal of Clinical Oncology, 2020, 38, 3090-3090.	1.6	10
17	Therapeutic modulation of the CD47-SIRPÎ± axis in the pediatric tumor microenvironment: working up an appetite. , 2020, 3, 550-562.		6
18	Immunotherapeutic Challenges for Pediatric Cancers. Molecular Therapy - Oncolytics, 2019, 15, 38-48.	4.4	26

#	Article	IF	Citations
19	First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial. Molecular Therapy, 2019, 27, 1930-1938.	8.2	41
20	GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival. Molecular Therapy - Oncolytics, 2019, 15, 214-222.	4.4	28
21	Immunotherapies for pediatric cancer: current landscape and future perspectives. Cancer and Metastasis Reviews, 2019, 38, 573-594.	5.9	20
22	Evidence for Oncolytic Viral Eradication of Cholesteatoma In Vitro. Otolaryngology - Head and Neck Surgery, 2019, 160, 891-893.	1.9	3
23	A Cationic Nanomicellar Complex of the Quaternary Amphiphilic Amine RC16+ with Fenretinide as a New Multitasking System for Antitumor Therapy. Current Drug Delivery, 2019, 16, 807-817.	1.6	1
24	After Hollywood Opened the Door, What Do We See in the Halls of Academic Medicine?. Academic Medicine, 2018, 93, 1099-1100.	1.6	0
25	Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment. Molecular Therapy - Oncolytics, 2018, 11, 62-74.	4.4	41
26	A multiyear quality improvement project to increase influenza vaccination in a pediatric oncology population undergoing active therapy. Pediatric Blood and Cancer, 2018, 65, e27268.	1.5	8
27	Pediatric Cancer Immunotherapy: Opportunities and Challenges. Paediatric Drugs, 2018, 20, 395-408.	3.1	76
28	Oncolytic virus and PD-1/PD-L1 blockade combination therapy. Oncolytic Virotherapy, 2018, Volume 7, 65-77.	6.0	57
29	Advances in the diagnosis and management of cardiomyopathy in Duchenne muscular dystrophy. Neuromuscular Disorders, 2018, 28, 711-716.	0.6	29
30	High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy. Viruses, 2018, 10, 132.	3.3	22
31	Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens. Pediatric Blood and Cancer, 2018, 65, e27313.	1.5	11
32	Please stand by: how oncolytic viruses impact bystander cells. Future Virology, 2018, 13, 671-680.	1.8	5
33	Immunotherapy for osteosarcoma: Where do we go from here?. Pediatric Blood and Cancer, 2018, 65, e27227.	1.5	117
34	Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget, 2018, 9, 21348-21358.	1.8	12
35	Reduction of cyclophosphamide dose for patients with subset 2 lowâ€risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Cancer, 2017, 123, 2368-2375.	4.1	60
36	Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients. Clinical Cancer Research, 2017, 23, 3566-3574.	7.0	105

#	Article	IF	Citations
37	Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models. Scientific Reports, 2017, 7, 2396.	3.3	62
38	Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule Drugs. Molecular Cancer Therapeutics, 2017, 16, 1555-1565.	4.1	38
39	A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. Cancer Research, 2017, 77, 5706-5711.	0.9	22
40	TGF-Î² Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma. Molecular Therapy - Oncolytics, 2017, 7, 17-26.	4.4	33
41	The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells. Immunity, 2017, 47, 159-170.e10.	14.3	27
42	Oncolytic Herpes Virus rRp450 Shows Efficacy in Orthotopic Xenograft Group 3/4 Medulloblastomas and Atypical Teratoid/Rhabdoid Tumors. Molecular Therapy - Oncolytics, 2017, 6, 22-30.	4.4	35
43	Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation. Oncotarget, 2017, 8, 17412-17427.	1.8	24
44	Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy. Oncotarget, 2017, 8, 82037-82048.	1.8	41
45	To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses. Viruses, 2016, 8, 43.	3.3	36
46	Tumor-Associated Macrophages in Oncolytic Virotherapy: Friend or Foe?. Biomedicines, 2016, 4, 13.	3.2	35
47	Characterization of MHC Class I and Î²â€2â€Microglobulin Expression in Pediatric Solid Malignancies to Guide Selection of Immuneâ€Based Therapeutic Trials. Pediatric Blood and Cancer, 2016, 63, 618-626.	1.5	12
48	Pediatric Oral/Maxillofacial Soft Tissue Sarcomas: A Clinicopathologic Report of Four Cases. Case Reports in Oncology, 2016, 9, 447-453.	0.7	0
49	Preparation and Evaluation of a Novel Class of Amphiphilic Amines as Antitumor Agents and Nanocarriers for Bioactive Molecules. Pharmaceutical Research, 2016, 33, 2722-2735.	3.5	3
50	Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of neurofibromatosis type 1. Pediatric Blood and Cancer, 2015, 62, 1709-1716.	1.5	59
51	Radiation therapy may increase metastatic potential in alveolar rhabdomyosarcoma. Pediatric Blood and Cancer, 2015, 62, 1550-1554.	1.5	11
52	Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children. Molecular Therapy - Oncolytics, 2015, 2, 15015.	4.4	19
53	Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in children. Molecular Therapy - Oncolytics, 2015, 2, 15016.	4.4	11
54	Going back to class I: MHC and immunotherapies for childhood cancer. Pediatric Blood and Cancer, 2015, 62, 571-576.	1.5	68

#	Article	IF	Citations
55	Phase 1 Study of Intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients. Molecular Therapy, 2015, 23, 602-608.	8.2	132
56	Nothing but NET: A review of norepinephrine transporter expression and efficacy of ¹³¹Iâ€mIBG therapy. Pediatric Blood and Cancer, 2015, 62, 5-11.	1.5	77
57	ET-27 * REPLICATION AND SPREAD OF ONCOLYTIC HERPES VIRUS IN GLIOMA STEM CELLS CAN BE ENHANCED BY SPECIFIC INHIBITION OF HISTONE DEACETYLASE 6. Neuro-Oncology, 2014, 16, v85-v85.	1.2	0
58	Bortezomib-Induced Unfolded Protein Response Increases Oncolytic HSV-1 Replication Resulting in Synergistic Antitumor Effects. Clinical Cancer Research, 2014, 20, 3787-3798.	7.0	61
59	Shorter-Duration Therapy Using Vincristine, Dactinomycin, and Lower-Dose Cyclophosphamide With or Without Radiotherapy for Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Journal of Clinical Oncology, 2014, 32, 3547-3552.	1.6	123
60	Doxorubicin Synergizes with 34.5ENVE to Enhance Antitumor Efficacy against Metastatic Ovarian Cancer. Clinical Cancer Research, 2014, 20, 6479-6494.	7.0	27
61	Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity. Molecular Therapy - Oncolytics, 2014, 1, 14010.	4.4	33
62	A Novel Class of Anticancer Compounds Targets the Actin Cytoskeleton in Tumor Cells. Cancer Research, 2013, 73, 5169-5182.	0.9	155
63	VEGF Blockade Enables Oncolytic Cancer Virotherapy in Part by Modulating Intratumoral Myeloid Cells. Molecular Therapy, 2013, 21, 1014-1023.	8.2	34
64	A phase I dose-escalation study of intratumoral herpes simplex virus-1 mutant HSV1716 in pediatric/young adult patients with refractory non-central nervous system solid tumors.. Journal of Clinical Oncology, 2013, 31, 10047-10047.	1.6	1
65	Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress. Current Pharmaceutical Biotechnology, 2012, 13, 1842-1851.	1.6	62
66	Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants. Pediatric Blood and Cancer, 2006, 46, 745-754.	1.5	39
67	Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses. Cancer Gene Therapy, 2005, 12, 407-416.	4.6	47
68	Oncolytic herpes simplex virus mutants are more efficacious than wildâ€type adenovirus Type 5 for the treatment of highâ€risk neuroblastomas in preclinical models. Pediatric Blood and Cancer, 2005, 44, 469-478.	1.5	35
69	Effect of Combined Cyclooxygenase-2 and Matrix Metalloproteinase Inhibition on Human Sarcoma Xenografts. Journal of Pediatric Hematology/Oncology, 2003, 25, 709-714.	0.6	17
70	Differential Susceptibility of Pediatric Sarcoma Cells to Oncolysis by Conditionally Replication-Competent Herpes Simplex Viruses. Journal of Pediatric Hematology/Oncology, 2002, 24, 447-453.	0.6	33
71	Ewing Sarcoma Family of Tumors Express Adenovirus Receptors and Are Susceptible to Adenovirus-Mediated Oncolysis. Journal of Pediatric Hematology/Oncology, 2002, 24, 527-533.	0.6	12
72	Emerging cancer-targeted therapies. Pediatric Clinics of North America, 2002, 49, 1339-1368.	1.8	7

#	Article	IF	Citations
73	EXLOITING GENETIC ALTERATIONS TO DESIGN NOVEL THERAPIES FOR CANCER. Hematology/Oncology Clinics of North America, 2001, 15, 657-675.	2.2	8